Hoyoung Huh, MD, PhD brings a wealth of expertise on transformational and emerging approaches to biological therapeutics and an extensive scientific and executive leadership background within the biotechnology industry. As former Chairman of Cytomx Therapeutics (NASDAQ:CTMX) and Chairman of Geron Corporation (NASDAQ:GERN), Dr. Huh has been involved in the formation, management and financing of more than 20 successful biotechnology entities across the United States, Europe and Asia. Dr. Huh was previously the president and CEO of BiPar Sciences Inc., which was acquired by Sanofi-aventis in 2009. He also served as the Chairman of Epizyme Inc. (NASDAQ:EPZM), chief operating officer and board member of Nektar Therapeutics (NASDAQ:NKTR), and board member of Facet Biotech (NASDAQ:FACT), which was acquired by Abbott Laboratories in 2010. Dr. Huh was formerly a partner at McKinsey & Company in the healthcare and technology practices. Dr. Huh holds a AB in biochemistry from Dartmouth College, an MD from Cornell University Medical College, and a PhD in genetics and cell biology from Cornell University/Sloan-Kettering Institute.